Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "NGO"

869 News Found

EU unveils draft guidance to fast-track clinical trials during public health emergencies
Policy | March 09, 2026

EU unveils draft guidance to fast-track clinical trials during public health emergencies

The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations


FDA nod to groundbreaking combo therapy for relapsed multiple myeloma
News | March 07, 2026

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile


Merck delivers resilient 2025 performance despite global headwinds
News | March 06, 2026

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results


NATCO announces launch of Pomalidomide capsules in US
News | March 05, 2026

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma


Ind-Swift earns EcoVadis silver medal for sustainability excellence
Sustainability | March 05, 2026

Ind-Swift earns EcoVadis silver medal for sustainability excellence

The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement


Teva and Blackstone Life Sciences strike $400m deal to advance promising IBD therapy
R&D | March 05, 2026

Teva and Blackstone Life Sciences strike $400m deal to advance promising IBD therapy

The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales


Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline
News | March 05, 2026

Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline

Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law


FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia
News | March 03, 2026

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia

Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications


Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS
Clinical Trials | March 02, 2026

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology